Tango Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 28.01 million compared to USD 25.21 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.29 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.31 USD | +2.89% | -7.35% | -26.16% |
08/05 | Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04/04 | British billionaire Joe Lewis fined $5 million by US judge for insider trading | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.16% | 759M | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- TNGX Stock
- News Tango Therapeutics, Inc.
- Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023